Research programme: osteoporosis therapeutics - Lexicon Pharmaceuticals

Drug Profile

Research programme: osteoporosis therapeutics - Lexicon Pharmaceuticals

Alternative Names: LX 5061

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexicon Genetics
  • Developer Lexicon Pharmaceuticals
  • Class Antibodies; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 08 Sep 2017 Pharmacodynamics data from a preclinical trial in Osteoporosis presented at the 39th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2017)
  • 13 Jan 2014 Discontinued - Preclinical for Osteoporosis in USA (PO)
  • 02 May 2007 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top